Skip to main content
Erschienen in: Gastric Cancer 1/2021

13.08.2020 | Original Article

Survival analysis of a prospective multicenter observational study on surgical palliation among patients receiving treatment for malignant gastric outlet obstruction caused by incurable advanced gastric cancer

verfasst von: Masanori Terashima, Kazumasa Fujitani, Masahiko Ando, Kentaro Sakamaki, Ryohei Kawabata, Yuichi Ito, Takaki Yoshikawa, Masato Kondo, Yasuhiro Kodera, Masahide Kaji, Yoshio Oka, Hiroshi Imamura, Junji Kawada, Akinori Takagane, Hideaki Shimada, Yutaka Tanizawa, Takeharu Yamanaka, Satoshi Morita, Motoki Ninomiya, Kazuhiro Yoshida

Erschienen in: Gastric Cancer | Ausgabe 1/2021

Einloggen, um Zugang zu erhalten

Abstract

Background

We had previously reported that surgical palliation could maintain quality of life (QOL) while improving solid food intake among patients with malignant gastric outlet obstruction (GOO) caused by advanced gastric cancer. The present study aimed to perform a survival analysis according to the patients’ QOL to elucidate its impact on survival.

Methods

Patients with GOO who underwent either palliative gastrectomy or gastrojejunostomy were included in this study. A validated QOL instrument (EQ-5D) was used to assess QOL at baseline and 2 weeks, 1 month, and 3 months following surgical palliation. Postoperative improvement in oral intake was also evaluated using the GOO scoring system (GOOSS). Thereafter, univariate and multivariate survival analyses were performed to determine independent prognostic factors.

Results

The median survival time of the 104 patients included herein was 11.30 months. Patients who received postoperative chemotherapy, PS 0/1, baseline EQ-5D ≥ 0.75, improved or stable EQ-5D, and improved oral intake expressed as GOOSS = 3 had significantly better survival. Multivariate analysis identified postoperative chemotherapy, a better baseline PS, a better baseline EQ5D, improved or stable EQ5D scores, and improved oral intake 3 months after surgical palliation as independent prognostic factors.

Conclusion

Apart from preoperative PS and postoperative chemotherapy, the present study identified better baseline QOL, improvement in postoperative QOL, and improvement in oral intake as prognostic factors among patients who underwent palliative surgery for advanced gastric cancer with GOO.
Literatur
1.
Zurück zum Zitat Ferlay J, Colombet M, Soerjomataram I, Mathers C, Parkin DM, Pineros M, et al. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. Int J Cancer. 2019;144:1941–53.CrossRef Ferlay J, Colombet M, Soerjomataram I, Mathers C, Parkin DM, Pineros M, et al. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. Int J Cancer. 2019;144:1941–53.CrossRef
2.
Zurück zum Zitat Ohtsu A. Chemotherapy for metastatic gastric cancer: past, present, and future. J Gastroenterol. 2008;43:256–64.CrossRef Ohtsu A. Chemotherapy for metastatic gastric cancer: past, present, and future. J Gastroenterol. 2008;43:256–64.CrossRef
3.
Zurück zum Zitat Gencer D, Kastle-Larralde N, Pilz LR, Weiss A, Buchheidt D, Hochhaus A, et al. Presentation, treatment, and analysis of prognostic factors of terminally ill patients with gastrointestinal tumors. Onkologie. 2009;32:380–6.CrossRef Gencer D, Kastle-Larralde N, Pilz LR, Weiss A, Buchheidt D, Hochhaus A, et al. Presentation, treatment, and analysis of prognostic factors of terminally ill patients with gastrointestinal tumors. Onkologie. 2009;32:380–6.CrossRef
4.
Zurück zum Zitat Fujitani K, Ando M, Sakamaki K, Terashima M, Kawabata R, Ito Y, et al. Multicentre observational study of quality of life after surgical palliation of malignant gastric outlet obstruction for gastric cancer. BJS Open. 2017;1:165–74.CrossRef Fujitani K, Ando M, Sakamaki K, Terashima M, Kawabata R, Ito Y, et al. Multicentre observational study of quality of life after surgical palliation of malignant gastric outlet obstruction for gastric cancer. BJS Open. 2017;1:165–74.CrossRef
5.
Zurück zum Zitat Chau I, Norman AR, Cunningham D, Waters JS, Oates J, Ross PJ. Multivariate prognostic factor analysis in locally advanced and metastatic esophago-gastric cancer–pooled analysis from three multicenter, randomized, controlled trials using individual patient data. J Clin Oncol. 2004;22:2395–403.CrossRef Chau I, Norman AR, Cunningham D, Waters JS, Oates J, Ross PJ. Multivariate prognostic factor analysis in locally advanced and metastatic esophago-gastric cancer–pooled analysis from three multicenter, randomized, controlled trials using individual patient data. J Clin Oncol. 2004;22:2395–403.CrossRef
6.
Zurück zum Zitat Park SH, Cho MS, Kim YS, Hong J, Nam E, Park J, et al. Self-reported health-related quality of life predicts survival for patients with advanced gastric cancer treated with first-line chemotherapy. Qual Life Res. 2008;17:207–14.CrossRef Park SH, Cho MS, Kim YS, Hong J, Nam E, Park J, et al. Self-reported health-related quality of life predicts survival for patients with advanced gastric cancer treated with first-line chemotherapy. Qual Life Res. 2008;17:207–14.CrossRef
7.
Zurück zum Zitat World Medical A. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA. 2013;310:2191–4.CrossRef World Medical A. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA. 2013;310:2191–4.CrossRef
8.
Zurück zum Zitat Rabin R, de Charro F. EQ-5D: a measure of health status from the EuroQol Group. Ann Med. 2001;33:337–43.CrossRef Rabin R, de Charro F. EQ-5D: a measure of health status from the EuroQol Group. Ann Med. 2001;33:337–43.CrossRef
9.
Zurück zum Zitat Vickery CW, Blazeby JM, Conroy T, Arraras J, Sezer O, Koller M, et al. Development of an EORTC disease-specific quality of life module for use in patients with gastric cancer. Eur J Cancer. 2001;37:966–71.CrossRef Vickery CW, Blazeby JM, Conroy T, Arraras J, Sezer O, Koller M, et al. Development of an EORTC disease-specific quality of life module for use in patients with gastric cancer. Eur J Cancer. 2001;37:966–71.CrossRef
10.
Zurück zum Zitat Blazeby JM, Conroy T, Bottomley A, Vickery C, Arraras J, Sezer O, et al. Clinical and psychometric validation of a questionnaire module, the EORTC QLQ-STO 22, to assess quality of life in patients with gastric cancer. Eur J Cancer. 2004;40:2260–8.CrossRef Blazeby JM, Conroy T, Bottomley A, Vickery C, Arraras J, Sezer O, et al. Clinical and psychometric validation of a questionnaire module, the EORTC QLQ-STO 22, to assess quality of life in patients with gastric cancer. Eur J Cancer. 2004;40:2260–8.CrossRef
11.
Zurück zum Zitat Navarra G, Musolino C, Venneri A, De Marco ML, Bartolotta M. Palliative antecolic isoperistaltic gastrojejunostomy: a randomized controlled trial comparing open and laparoscopic approaches. Surg Endosc. 2006;20:1831–4.CrossRef Navarra G, Musolino C, Venneri A, De Marco ML, Bartolotta M. Palliative antecolic isoperistaltic gastrojejunostomy: a randomized controlled trial comparing open and laparoscopic approaches. Surg Endosc. 2006;20:1831–4.CrossRef
12.
Zurück zum Zitat Pickard AS, Neary MP, Cella D. Estimation of minimally important differences in EQ-5D utility and VAS scores in cancer. Health Qual Life Outcomes. 2007;5:70.CrossRef Pickard AS, Neary MP, Cella D. Estimation of minimally important differences in EQ-5D utility and VAS scores in cancer. Health Qual Life Outcomes. 2007;5:70.CrossRef
13.
Zurück zum Zitat Fujitani K, Yang HK, Mizusawa J, Kim YW, Terashima M, Han SU, et al. Gastrectomy plus chemotherapy versus chemotherapy alone for advanced gastric cancer with a single non-curable factor (REGATTA): a phase 3, randomised controlled trial. Lancet Oncol. 2016;17:309–18.CrossRef Fujitani K, Yang HK, Mizusawa J, Kim YW, Terashima M, Han SU, et al. Gastrectomy plus chemotherapy versus chemotherapy alone for advanced gastric cancer with a single non-curable factor (REGATTA): a phase 3, randomised controlled trial. Lancet Oncol. 2016;17:309–18.CrossRef
14.
Zurück zum Zitat Jeurnink SM, van Eijck CH, Steyerberg EW, Kuipers EJ, Siersema PD. Stent versus gastrojejunostomy for the palliation of gastric outlet obstruction: a systematic review. BMC Gastroenterol. 2007;7:18.CrossRef Jeurnink SM, van Eijck CH, Steyerberg EW, Kuipers EJ, Siersema PD. Stent versus gastrojejunostomy for the palliation of gastric outlet obstruction: a systematic review. BMC Gastroenterol. 2007;7:18.CrossRef
15.
Zurück zum Zitat Jeurnink SM, Steyerberg EW, van Hooft JE, van Eijck CH, Schwartz MP, Vleggaar FP, et al. Surgical gastrojejunostomy or endoscopic stent placement for the palliation of malignant gastric outlet obstruction (SUSTENT study): a multicenter randomized trial. Gastrointest Endosc. 2010;71:490–9.CrossRef Jeurnink SM, Steyerberg EW, van Hooft JE, van Eijck CH, Schwartz MP, Vleggaar FP, et al. Surgical gastrojejunostomy or endoscopic stent placement for the palliation of malignant gastric outlet obstruction (SUSTENT study): a multicenter randomized trial. Gastrointest Endosc. 2010;71:490–9.CrossRef
16.
Zurück zum Zitat Lasithiotakis K, Antoniou SA, Antoniou GA, Kaklamanos I, Zoras O. Gastrectomy for stage IV gastric cancer. a systematic review and meta-analysis. Anticancer Res. 2014;34:2079–85.PubMed Lasithiotakis K, Antoniou SA, Antoniou GA, Kaklamanos I, Zoras O. Gastrectomy for stage IV gastric cancer. a systematic review and meta-analysis. Anticancer Res. 2014;34:2079–85.PubMed
17.
Zurück zum Zitat Omori H, Tanizawa Y, Makuuchi R, Irino T, Bando E, Kawamura T, et al. Role of palliative resection in patients with incurable advanced gastric cancer who are unfit for chemotherapy. World J Surg. 2019;43:571–9.CrossRef Omori H, Tanizawa Y, Makuuchi R, Irino T, Bando E, Kawamura T, et al. Role of palliative resection in patients with incurable advanced gastric cancer who are unfit for chemotherapy. World J Surg. 2019;43:571–9.CrossRef
18.
Zurück zum Zitat Kahlke V, Bestmann B, Schmid A, Doniec JM, Kuchler T, Kremer B. Palliation of metastatic gastric cancer: impact of preoperative symptoms and the type of operation on survival and quality of life. World J Surg. 2004;28:369–75.CrossRef Kahlke V, Bestmann B, Schmid A, Doniec JM, Kuchler T, Kremer B. Palliation of metastatic gastric cancer: impact of preoperative symptoms and the type of operation on survival and quality of life. World J Surg. 2004;28:369–75.CrossRef
19.
Zurück zum Zitat Mahar AL, Coburn NG, Karanicolas PJ, Viola R, Helyer LK. Effective palliation and quality of life outcomes in studies of surgery for advanced, non-curative gastric cancer: a systematic review. Gastric Cancer. 2012;15(Suppl 1):S138–S145145.CrossRef Mahar AL, Coburn NG, Karanicolas PJ, Viola R, Helyer LK. Effective palliation and quality of life outcomes in studies of surgery for advanced, non-curative gastric cancer: a systematic review. Gastric Cancer. 2012;15(Suppl 1):S138–S145145.CrossRef
20.
Zurück zum Zitat Martin AJ, Gibbs E, Sjoquist K, Pavlakis N, Simes J, Price T, et al. Health-related quality of life associated with regorafenib treatment in refractory advanced gastric adenocarcinoma. Gastric Cancer. 2018;21:473–80.CrossRef Martin AJ, Gibbs E, Sjoquist K, Pavlakis N, Simes J, Price T, et al. Health-related quality of life associated with regorafenib treatment in refractory advanced gastric adenocarcinoma. Gastric Cancer. 2018;21:473–80.CrossRef
21.
Zurück zum Zitat Shitara K, Ito S, Sawaki A, Tajika M, Kawai H, Yokota T, et al. Improvement of oral intake following chemotherapy in gastric cancer patients with an inability to eat. Oncology. 2010;79:211–8.CrossRef Shitara K, Ito S, Sawaki A, Tajika M, Kawai H, Yokota T, et al. Improvement of oral intake following chemotherapy in gastric cancer patients with an inability to eat. Oncology. 2010;79:211–8.CrossRef
Metadaten
Titel
Survival analysis of a prospective multicenter observational study on surgical palliation among patients receiving treatment for malignant gastric outlet obstruction caused by incurable advanced gastric cancer
verfasst von
Masanori Terashima
Kazumasa Fujitani
Masahiko Ando
Kentaro Sakamaki
Ryohei Kawabata
Yuichi Ito
Takaki Yoshikawa
Masato Kondo
Yasuhiro Kodera
Masahide Kaji
Yoshio Oka
Hiroshi Imamura
Junji Kawada
Akinori Takagane
Hideaki Shimada
Yutaka Tanizawa
Takeharu Yamanaka
Satoshi Morita
Motoki Ninomiya
Kazuhiro Yoshida
Publikationsdatum
13.08.2020
Verlag
Springer Singapore
Erschienen in
Gastric Cancer / Ausgabe 1/2021
Print ISSN: 1436-3291
Elektronische ISSN: 1436-3305
DOI
https://doi.org/10.1007/s10120-020-01114-z

Weitere Artikel der Ausgabe 1/2021

Gastric Cancer 1/2021 Zur Ausgabe

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

CME: 2 Punkte

Prof. Dr. med. Gregor Antoniadis Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

CME: 2 Punkte

Dr. med. Benjamin Meyknecht, PD Dr. med. Oliver Pieske Das Webinar S2e-Leitlinie „Distale Radiusfraktur“ beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

CME: 2 Punkte

Dr. med. Mihailo Andric
Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.